Apixaban Therapy
Find information on Apixaban Therapy (Eliquis), a Factor Xa Inhibitor, for healthcare professionals. Learn about clinical documentation, medical coding, and Apixaban dosage for accurate patient care. This resource covers essential aspects of Eliquis therapy, including administration, monitoring, and potential interactions, crucial for precise medical coding and optimal clinical documentation.
Anticoagulant used to prevent blood clots.
Reduces risk of stroke, DVT, and PE. May cause bleeding.
Atrial fibrillation, post-op orthopedic surgery, DVT/PE treatment.
ICD-10 Code Families
Complete code families applicable to Z79.01
When to use each related code
| Description | When to use |
|---|---|
| Treatment with apixaban, an oral anticoagulant. | Use for non-valvular atrial fibrillation, DVT/PE treatment and prevention, and post-orthopedic surgery. |
| Treatment with rivaroxaban, an oral anticoagulant. | Use for non-valvular atrial fibrillation, DVT/PE treatment and prevention, and reduction of stroke risk. |
| Treatment with warfarin, an oral anticoagulant. | Use for atrial fibrillation, venous thromboembolism, prosthetic heart valves, and after MI. |
Best-practice checklist
- ✓Apixaban (Eliquis) indication documented
- ✓Dosage, frequency, and route specified
- ✓Baseline renal/hepatic function assessed
- ✓Patient education on bleeding risk documented
- ✓Reason for Factor Xa inhibitor choice noted
Common pitfalls to avoid
Missing dosage strength and frequency for Apixaban (Eliquis) can lead to incorrect billing and patient safety concerns.
Lack of clear documentation for the medical necessity of Apixaban (Factor Xa Inhibitor) therapy can trigger denials.
Miscoding Apixaban (Eliquis) with other anticoagulants due to similar indications requires careful CDI review for accurate coding.
Best-practice tips
- 01Document apixaban indication, dosage, and duration for accurate ICD-10-CM coding.
- 02Query physician for clarity if apixaban intent is unclear (prophylaxis vs treatment).
- 03Ensure medical necessity for Eliquis is documented to support billing and compliance.
- 04Monitor renal function and drug interactions for patient safety and optimal apixaban use.
- 05Educate patients on bleeding risks, dosage instructions, and importance of compliance.
Step-by-step checklist
- 1
Verify CrCl > 15 mL/min (Apixaban dose adjustment)
- 2
Check for active pathological bleeding
- 3
Document drug interactions (azole antifungals, etc.)
- 4
Assess patient risk of falls/bleeding events
- 5
Patient education on bleeding precautions provided
Ready-to-paste narrative
Patient presents for management of Apixaban therapy, also known as Eliquis therapy, for the prevention or treatment of thromboembolic events. The patient's indication for Apixaban, a Factor Xa inhibitor, was discussed, including a review of potential benefits and risks such as bleeding complications, drug interactions, and the need for consistent medication adherence. Current medication list was reviewed and reconciled. Patient demonstrated understanding of the importance of regular laboratory monitoring, if applicable, as well as when to seek immediate medical attention for signs or symptoms of bleeding or thromboembolism. Patient education regarding dietary considerations while on Apixaban therapy, including limitations on certain foods and supplements, was provided. The prescribed dosage, frequency, and route of administration of Apixaban were thoroughly explained. The patient's renal function and potential drug interactions were assessed as part of medication management. Follow-up appointment was scheduled to monitor treatment efficacy and address any potential adverse effects associated with Apixaban or Eliquis use. The discussion included alternative anticoagulation options and the rationale for selecting Apixaban. This documentation supports medical billing and coding for Apixaban therapy management.
Common questions and answers
What are the key considerations for managing apixaban therapy in patients with renal impairment?+
Managing apixaban (Eliquis), a factor Xa inhibitor, in patients with renal impairment requires careful dose adjustments based on creatinine clearance. For patients with a creatinine clearance of 15-29 mL/min, a reduced dose of 2.5 mg twice daily is recommended. For those with a creatinine clearance less than 15 mL/min or on dialysis, apixaban is generally avoided due to limited data and increased bleeding risk. Close monitoring for signs of bleeding and regular assessment of renal function are crucial for optimal apixaban therapy management in these patients. Explore how our clinical decision support tools can help streamline renal dose adjustments for apixaban and other anticoagulants.
How do I reverse apixaban (Eliquis) in the event of a major bleed or urgent surgery?+
Reversing the anticoagulant effects of apixaban in emergency situations requires prompt action. Andexanet alfa (Andexxa) is a specific reversal agent approved for apixaban-induced bleeding. While four-factor prothrombin complex concentrate (PCC) can be considered if andexanet alfa is unavailable, its efficacy is less established. For life-threatening bleeds, immediate cessation of apixaban and supportive measures are paramount. Consider implementing a standardized protocol for anticoagulant reversal in your practice to ensure rapid and appropriate management of such events. Learn more about the latest guidelines for managing anticoagulation-related bleeding complications.
When should I consider switching a patient from warfarin to apixaban (Eliquis), and what precautions should I take during the transition?+
Switching a patient from warfarin, a vitamin K antagonist, to apixaban, a direct oral anticoagulant (DOAC), can offer several advantages, including simplified dosing and fewer drug interactions. However, careful transition is essential to minimize thrombotic risk. Generally, apixaban is initiated 12-24 hours after the last dose of warfarin when the INR is below the therapeutic range. Close INR monitoring is vital during this transition period. Patients with specific conditions, such as mechanical heart valves, should not be switched to apixaban. Explore our resources for evidence-based strategies for transitioning patients between anticoagulants safely and effectively.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.